1
|
Suckling CJ. The allure of targets for novel drugs. RSC Med Chem 2024; 15:472-484. [PMID: 38389887 PMCID: PMC10880906 DOI: 10.1039/d3md00621b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 12/12/2023] [Indexed: 02/24/2024] Open
Abstract
The challenges of bringing new medicines to patients have been extensively discussed and debated, including consideration of the contribution that academic laboratories can make. At the University of Strathclyde, drug discovery has been a continuing focal activity since the 1960s, and in the past 30 years, the author has led or contributed to many projects of different character and for diverse diseases. A feature common to these projects is the extension of concepts of molecular and biological targets in drug discovery research. In mechanistic terms, these have included compounds that are activators and not inhibitors, and in particular multitargeted compounds. With respect to relevance to disease, schizophrenia, pulmonary disfunction, autoimmune, and infectious disease are most relevant. These projects are discussed in the context of classical medicinal chemistry and more recent concepts in and approaches to drug discovery.
Collapse
Affiliation(s)
- Colin J Suckling
- Department of Pure & Applied Chemistry, University of Strathclyde 295 Cathedral Street Glasgow G1 1Xl Scotland UK
| |
Collapse
|
2
|
Identification of Novel Dopamine D2 Receptor Ligands—A Combined In Silico/In Vitro Approach. Molecules 2022; 27:molecules27144435. [PMID: 35889317 PMCID: PMC9318694 DOI: 10.3390/molecules27144435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 07/05/2022] [Accepted: 07/06/2022] [Indexed: 02/04/2023] Open
Abstract
Diseases of the central nervous system are an alarming global problem showing an increasing prevalence. Dopamine receptor D2 (D2R) has been shown to be involved in central nervous system diseases. While different D2R-targeting drugs have been approved by the FDA, they all suffer from major drawbacks due to promiscuous receptor activity leading to adverse effects. Increasing the number of potential D2R-targeting drug candidates bears the possibility of discovering molecules with less severe side-effect profiles. In dire need of novel D2R ligands for drug development, combined in silico/in vitro approaches have been shown to be efficient strategies. In this study, in silico pharmacophore models were generated utilizing both ligand- and structure-based approaches. Subsequently, different databases were screened for novel D2R ligands. Selected virtual hits were investigated in vitro, quantifying their binding affinity towards D2R. This workflow successfully identified six novel D2R ligands exerting micro- to nanomolar (most active compound KI = 4.1 nM) activities. Thus, the four pharmacophore models showed prospective true-positive hit rates in between 4.5% and 12%. The developed workflow and identified ligands could aid in developing novel drug candidates for D2R-associated pathologies.
Collapse
|
3
|
Eger E, Schrittwieser JH, Wetzl D, Iding H, Kuhn B, Kroutil W. Asymmetric Biocatalytic Synthesis of 1-Aryltetrahydro-β-carbolines Enabled by "Substrate Walking". Chemistry 2020; 26:16281-16285. [PMID: 33017078 PMCID: PMC7756766 DOI: 10.1002/chem.202004449] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Indexed: 12/19/2022]
Abstract
Stereoselective catalysts for the Pictet-Spengler reaction of tryptamines and aldehydes may allow a simple and fast approach to chiral 1-substituted tetrahydro-β-carbolines. Although biocatalysts have previously been employed for the Pictet-Spengler reaction, not a single one accepts benzaldehyde and its substituted derivatives. To address this challenge, a combination of substrate walking and transfer of beneficial mutations between different wild-type backbones was used to develop a strictosidine synthase from Rauvolfia serpentina (RsSTR) into a suitable enzyme for the asymmetric Pictet-Spengler condensation of tryptamine and benzaldehyde derivatives. The double variant RsSTR V176L/V208A accepted various ortho-, meta- and para-substituted benzaldehydes and produced the corresponding chiral 1-aryl-tetrahydro-β-carbolines with up to 99 % enantiomeric excess.
Collapse
Affiliation(s)
- Elisabeth Eger
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
| | - Joerg H. Schrittwieser
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
| | - Dennis Wetzl
- Process Chemistry & CatalysisF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Hans Iding
- Process Chemistry & CatalysisF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Bernd Kuhn
- Pharma Research & Early DevelopmentF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Wolfgang Kroutil
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
- Field of Excellence BioHealth—University of Graz8010GrazAustria
| |
Collapse
|
4
|
Kaczor AA, Targowska-Duda KM, Silva AG, Kondej M, Biała G, Castro M. N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1 H- benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic. Biomolecules 2020; 10:E349. [PMID: 32102432 PMCID: PMC7072648 DOI: 10.3390/biom10020349] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Revised: 02/17/2020] [Accepted: 02/18/2020] [Indexed: 12/20/2022] Open
Abstract
N-(2-hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol -1-yl)propyl]piperidine-4-carboxamide (D2AAK4) is a multitarget ligand of aminergic G protein-coupled receptors (GPCRs) identified in structure-based virtual screening. Here we present detailed in vitro, in silico and in vivo investigations of this virtual hit. D2AAK4 has an atypical antipsychotic profile and low affinity to off-targets. It interacts with aminergic GPCRs, forming an electrostatic interaction between its protonatable nitrogen atom and the conserved Asp 3.32 of the receptors. At the dose of 100 mg/kg D2AAK4 decreases amphetamine-induced hyperactivity predictive of antipsychotic activity, improves memory consolidation in passive avoidance test and has anxiogenic properties in elevated plus maze test (EPM). Further optimization of the virtual hit D2AAK4 will be aimed to balance its multitarget profile and to obtain analogs with anxiolytic activity.
Collapse
Affiliation(s)
- Agnieszka A. Kaczor
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland;
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Katarzyna M. Targowska-Duda
- Department of Biopharmacy, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland
| | - Andrea G. Silva
- Department of Pharmacology, Universidade de Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Avda de Barcelona, E-15782 Santiago de Compostela, Spain; (A.G.S.); (M.C.)
| | - Magda Kondej
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland;
| | - Grażyna Biała
- Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland;
| | - Marián Castro
- Department of Pharmacology, Universidade de Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Avda de Barcelona, E-15782 Santiago de Compostela, Spain; (A.G.S.); (M.C.)
| |
Collapse
|
5
|
Szulczyk D, Bielenica A, Kędzierska E, Leśniak A, Pawłowska A, Bujalska-Zadrożny M, Saccone I, Sparaco R, Fiorino F, Savchenko O, Struga M. G protein-coupled receptor binding and pharmacological evaluation of indole-derived thiourea compounds. Arch Pharm (Weinheim) 2019; 353:e1900218. [PMID: 31782553 DOI: 10.1002/ardp.201900218] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 10/18/2019] [Accepted: 11/15/2019] [Indexed: 12/16/2022]
Abstract
Four 2-(1H-indol-3-yl)ethylthiourea derivatives were prepared by condensation of 2-(1H-indol-3-yl)ethanamine with the corresponding aryl/alkylisothiocyanates in a medium-polarity solvent. Their structures were confirmed by spectral techniques, and the molecular structure of 3 was determined by X-ray crystal analysis. For all derivatives, the binding affinities at the 5-HT2A and 5-HT2C receptors, as well as their functional activities at the 5-HT1A and D2 receptors, were determined. The arylthioureas 1 and 4 were the most active at the 5-HT1A receptor, showing, at the same time, significant selectivity over the studied 5-HT2 and D2 receptor subtypes. The compounds were tested for their pharmacological activities within the central nervous system in relevant mouse models. The involvement of the serotonergic system in the activity of 1 and 4 was indicated. The antinociceptive action of 4 was linked to its anti-inflammatory activity.
Collapse
Affiliation(s)
- Daniel Szulczyk
- Department of Biochemistry, Medical University of Warsaw, Warszawa, Poland
| | - Anna Bielenica
- Department of Biochemistry, Medical University of Warsaw, Warszawa, Poland
| | - Ewa Kędzierska
- Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Lublin, Poland
| | - Anna Leśniak
- Department of Pharmacodynamics, Medicine Division, Centre for Preclinical Research and Technology, Faculty of Pharmacy with the Laboratory, Medical University of Warsaw, Warszawa, Poland
| | - Agata Pawłowska
- Department of Pharmacodynamics, Medicine Division, Centre for Preclinical Research and Technology, Faculty of Pharmacy with the Laboratory, Medical University of Warsaw, Warszawa, Poland
| | - Magdalena Bujalska-Zadrożny
- Department of Pharmacodynamics, Medicine Division, Centre for Preclinical Research and Technology, Faculty of Pharmacy with the Laboratory, Medical University of Warsaw, Warszawa, Poland
| | - Irene Saccone
- Department of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Rosa Sparaco
- Department of Pharmacy, University of Naples Federico II, Naples, Italy
| | | | | | - Marta Struga
- Department of Biochemistry, Medical University of Warsaw, Warszawa, Poland
| |
Collapse
|
6
|
Hirasawa Y, Dai X, Deguchi J, Hatano S, Sasaki T, Ohtsuka R, Nugroho AE, Kaneda T, Morita H. New vasorelaxant indole alkaloids, taberniacins A and B, from Tabernaemontana divaricata. J Nat Med 2019; 73:627-632. [PMID: 30847757 DOI: 10.1007/s11418-019-01293-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 02/20/2019] [Indexed: 10/27/2022]
Abstract
Taberniacins A (1) and B (2), new indole alkaloids, were isolated from the stems of Tabernaemontana divaricata (Apocynaceae). Structure elucidation of 1 and 2 was based on spectroscopic methods and total synthesis. Each alkaloid showed vasorelaxant activity against phenylephrine-induced contraction of isolated rat aorta.
Collapse
Affiliation(s)
- Yusuke Hirasawa
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Xin Dai
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Jun Deguchi
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Shota Hatano
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Tadahiro Sasaki
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Ruri Ohtsuka
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Alfarius Eko Nugroho
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Toshio Kaneda
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan
| | - Hiroshi Morita
- Faculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
| |
Collapse
|
7
|
Albano G, Morelli M, Lissia M, Aronica LA. Synthesis of Functionalised Indoline and Isoquinoline Derivatives through a Silylcarbocyclisation/Desilylation Sequence. ChemistrySelect 2019. [DOI: 10.1002/slct.201900524] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Gianluigi Albano
- Dipartimento di Chimica e Chimica Industriale; University of Pisa, Via G. Moruzzi 13; 56124 Pisa Italy Fax: (+)390502219260
| | - Martina Morelli
- Dipartimento di Chimica e Chimica Industriale; University of Pisa, Via G. Moruzzi 13; 56124 Pisa Italy Fax: (+)390502219260
| | - Margherita Lissia
- Dipartimento di Chimica e Chimica Industriale; University of Pisa, Via G. Moruzzi 13; 56124 Pisa Italy Fax: (+)390502219260
| | - Laura A. Aronica
- Dipartimento di Chimica e Chimica Industriale; University of Pisa, Via G. Moruzzi 13; 56124 Pisa Italy Fax: (+)390502219260
| |
Collapse
|
8
|
|
9
|
Kucwaj-Brysz K, Kurczab R, Żesławska E, Lubelska A, Marć MA, Latacz G, Satała G, Nitek W, Kieć-Kononowicz K, Handzlik J. The role of aryl-topology in balancing between selective and dual 5-HT 7R/5-HT 1A actions of 3,5-substituted hydantoins. MEDCHEMCOMM 2018; 9:1033-1044. [PMID: 30108992 DOI: 10.1039/c8md00168e] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 05/04/2018] [Indexed: 11/21/2022]
Abstract
In order to search for active and selective serotonin 5-HT7R antagonists among 3,5-disubstituted arylpiperazine-imidazolidine-2,4-diones, the role of the introduction/deletion and the mutual orientation of aromatic rings was analyzed. Chemical modifications of 2nd generation lead structure of 3-(3-(4-(diphenylmethyl)piperazin-1-yl)-2-hydroxypropyl)-5-(4-fluorophenyl)-5-methylimidazolidine-2,4-dione (2, KKB16) were performed. New derivatives (4-18) were designed and synthesized. X-ray crystallographic analysis of the representative compound 5-(4-fluorophenyl)-3-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-5-methylimidazolidine-2,4-dione (3) was performed to support molecular modeling and SAR studies. The affinity for 5-HT7R, D2R and 5-HT1AR in radioligand binding assays for the entire series and ADME-Tox parameters in vitro for selected compounds (7, 10, and 13) were evaluated. Molecular docking and pharmacophore model assessment were performed. According to the obtained results, 5-methyl-5-naphthylhydantoin derivatives were found to be the new highly active 5-HT7R agents (Ki ≤ 5 nM) with significant selectivity over 5-HT1AR and D2R. On the contrary, the (1-naphthyl)piperazine moiety was gained with the potent dual 5-HT7R/5-HT1AR action (Ki: 11 nM/19 nM).
Collapse
Affiliation(s)
- Katarzyna Kucwaj-Brysz
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| | - Rafał Kurczab
- Department of Medicinal Chemistry Institute of Pharmacology , Polish Academy of Science , Smętna 12 , 31-343 , Cracow , Poland
| | - Ewa Żesławska
- Department of Chemistry , Institute of Biology , Pedagogical University of Cracow , Podchorążych 2 , 30-084 Cracow , Poland
| | - Annamaria Lubelska
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| | - Małgorzata Anna Marć
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| | - Gniewomir Latacz
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| | - Grzegorz Satała
- Department of Medicinal Chemistry Institute of Pharmacology , Polish Academy of Science , Smętna 12 , 31-343 , Cracow , Poland
| | - Wojciech Nitek
- Faculty of Chemistry , Jagiellonian University , Gronostajowa 2 , 30-387 , Cracow , Poland
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Medyczna 9 , 30-688 Cracow , Poland . ; Tel: +012 620 55 80
| |
Collapse
|
10
|
He Z, Liu H, Liu H, Qian Q, Meng Q, Mei Q, Han B. Heterogeneous Cobalt-Catalyzed DirectN-Formylation of Isoquinolines with CO2and H2. ChemCatChem 2017. [DOI: 10.1002/cctc.201601682] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Zhenhong He
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
| | - Hangyu Liu
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
- University of Chinese Academy of Sciences; Beijing China
| | - Huizhen Liu
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
- University of Chinese Academy of Sciences; Beijing China
| | - Qingli Qian
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
| | - Qinglei Meng
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
| | - Qingqing Mei
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
- University of Chinese Academy of Sciences; Beijing China
| | - Buxing Han
- Beijing National Laboratory for Molecular Sciences (BNLMS); Institute of Chemistry; Chinese Academy of Sciences; 100190 Beijing China
- University of Chinese Academy of Sciences; Beijing China
| |
Collapse
|
11
|
Abstract
Psychopharmacology of schizophrenia has remained static for many years because the mechanisms explored have been basically monoaminergics, primarily focused toward the modification of dopaminergic function and, later on, serotonergic. In fact, most of the antipsychotics introduced in clinical practice in the last years have been antagonists or selective agonists of these receptors (D(2)/5-HT(2)). The exploration of other receptor pathways, and in particular those additionally involved in the action of the paradigmatic "atypical" antipsychotic clozapine (ie, cholinergic and noradrenergic), has not been very significant. Besides, research in the antipsychotics field has developed also by exploring pathways that are beyond the spectrum of clozapine. Among the most promising mechanisms are those based on the glutamatergic hypothesis of schizophrenia (agonists at the glycine-binding modulatory site of the N-methyl-D-aspartate receptor, glycine transporter inhibitors, modulators of the AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid] receptor and selective agonists of the metabotropic receptor Glu(2)). Other less classic pathways are also under study and have led to some agents that are found in very early stages of development such as those acting on sigma receptors, cholecystokinin antagonists, neurotensin agonists, neurokinin receptor antagonists, GABAergic (+-aminobutyric acid [GABA]) enhancers, and cannabinoid(gamma-aminobutiric) receptor modulators.
Collapse
|
12
|
Hayes DJ, Greenshaw AJ. 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev 2011; 35:1419-49. [PMID: 21402098 DOI: 10.1016/j.neubiorev.2011.03.005] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2010] [Revised: 03/03/2011] [Accepted: 03/04/2011] [Indexed: 01/07/2023]
Abstract
The brain's serotonin (5-HT) system is key in the regulation of reward-related behaviours, from eating and drinking to sexual activity. The complexity of studying this system is due, in part, to the fact that 5-HT acts at many receptor subtypes throughout the brain. The recent development of drugs with greater selectivity for individual receptor subtypes has allowed for rapid advancements in our understanding of this system. Use of these drugs in combination with animal models entailing selective reward measures (i.e. intracranial self-stimulation, drug self-administration, conditioned place preference) have resulted in a greater understanding of the pharmacology of reward-related processing and behaviour (particularly regarding drugs of abuse). The putative roles of each 5-HT receptor subtype in the pharmacology of reward are outlined and discussed here. It is concluded that the actions of 5-HT in reward are receptor subtype-dependent (and thus should not be generalized) and that all studied subtypes appear to have a unique profile which is determined by content (e.g. receptor function, localization - both throughout the brain and within the synapse) and context (e.g. type of behavioural paradigm, type of drug). Given evidence of altered reward-related processing and serotonergic function in numerous neuropsychiatric disorders, such as depression, schizophrenia, and addiction, a clearer understanding of the role of 5-HT receptor subtypes in this context may lead to improved drug development and therapeutic approaches.
Collapse
Affiliation(s)
- Dave J Hayes
- Centre for Neuroscience, 513 HMRC, University of Alberta, Edmonton, AB, T6G 2S2, Canada.
| | | |
Collapse
|
13
|
Leopoldo M, Lacivita E, Berardi F, Perrone R. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009). Expert Opin Ther Pat 2010; 20:739-54. [PMID: 20476847 DOI: 10.1517/13543776.2010.484802] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
IMPORTANCE OF THE FIELD The 5-HT(7) receptors are discretely localized within the CNS (thalamus, hypothalamus, limbic and cortical regions). The 5-HT(7) receptors are also present in smooth muscle cells from blood vessels and have been reported in gastrointestinal tract as well as in rat lumbar dorsal root and sympathetic ganglia. The 5-HT(7) receptors have been implicated in depression, disorders related to circadian rhythms, pain and migraine. Thus, there is a great interest in developing potent and selective 5-HT(7) receptor modulators. AREAS COVERED IN THIS REVIEW This review article highlights the research advances published in the patent literature between January 2004 and December 2009, giving emphasis to the medicinal chemist's standpoint. WHAT THE READER WILL GAIN Readers will rapidly gain an overview of the various 5-HT(7) receptor modulators reported in the patent literature in the past 6 years. Furthermore, the readers will learn which structure type can interact with 5-HT(7) receptor and also the different companies that are the main players in the field. TAKE HOME MESSAGE Although no 5-HT(7) modulator has entered clinical trials, the development and future use of different agonists and antagonists suitable for use in vivo seem very promising.
Collapse
Affiliation(s)
- Marcello Leopoldo
- Dipartimento Farmaco-Chimico, Università degli Studi di Bari A. Moro, via Orabona 4, Bari 70125, Italy.
| | | | | | | |
Collapse
|
14
|
Holló B, Leovac VM, Bombicz P, Kovács A, Jovanović LS, Bogdanović G, Kojić V, Divjaković V, Joksović MD, Szécsényi KM. Synthesis, Structural, DFT, and Cytotoxicity Studies of CuII and NiII Complexes with 3-Aminopyrazole Derivatives. Aust J Chem 2010. [DOI: 10.1071/ch10210] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Template synthesis of N,N′-bis(4-acetyl-5-methylpyrazole-3-yl)formamidine (ampf) was performed starting from 4-acetyl-3-amino-5-methylpyrazole (aamp) and CH(OC2H5)3 in methanol in the presence of CuCl2, Cu(NO3)2, or Ni(NO3)2. The ligand was isolated in coordinated form as [Cu(ampf)Cl2], [Cu(ampf)(MeOH)(NO3)2]MeOH, and [Ni(ampf)(MeOH)2(NO3)]NO3 correspondingly. The compounds were characterized by elemental analysis, Fourier-transform IR and electronic spectroscopy, thermal analysis, single-crystal X-ray diffraction, and quantum chemical (density functional theory) calculations. The density functional theory calculations provided information on the metal–ligand interactions in the complexes and assisted the assignment of the FT-IR spectra. The antiproliferative activity of the complexes and the ligand precursor, aamp, was tested against human myelogenous leukaemia K562, colon adenocarcinoma HT29, and cervix carcinoma HeLa.
Collapse
|
15
|
Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18:1715-26. [DOI: 10.1517/13543780903286388] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
16
|
Abstract
PURPOSE OF REVIEW In this article, we will summarize some of the most recent pharmacological approaches by briefly reviewing the latest research results related to different neurotransmitter receptor systems but also alternative approaches that do not affect central nervous system receptors directly. RECENT FINDINGS Although the field still struggles with the lack of major breakthroughs, some novel pharmacological leads have provided encouraging findings in proof of concept or early phase II clinical trials. Although some of these approaches are based on the modified dopamine/glutamate hypothesis of schizophrenia, others appear to have been driven by more serendipitous observations. Apart from this, more traditional routes such as compounds targeting D2/HT2 receptors are also still being pursued. Attempts to advance treatment response of negative symptoms and cognitive impairment, two areas of considerable unmet need have been an overriding theme in many studies. SUMMARY Clinical psychopharmacologists increasingly realize that it is highly unlikely that we have a magic bullet to treat adequately all aspects of this complex disorder in the foreseeable future. Rational polypharmacy may be the trend for the next decade.
Collapse
|
17
|
Peters JU, Lübbers T, Alanine A, Kolczewski S, Blasco F, Steward L. Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett 2007; 18:256-61. [PMID: 17998160 DOI: 10.1016/j.bmcl.2007.10.080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2007] [Revised: 10/22/2007] [Accepted: 10/25/2007] [Indexed: 10/22/2022]
Abstract
The optimisation of affinity and selectivity in a novel series of dual 5-HT5A/5-HT7 receptor ligands is described. Brain penetrant 2-aminodihydroquinazolines with low nanomolar affinities were identified.
Collapse
Affiliation(s)
- Jens-Uwe Peters
- Discovery Chemistry, Pharma Division, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
| | | | | | | | | | | |
Collapse
|